ASN 51
Alternative Names: ASN-51Latest Information Update: 28 Mar 2026
At a glance
- Originator Asceneuron
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Hexosaminidase C inhibitors; Muscarinic M1 receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- Phase I Parkinson's disease
Most Recent Events
- 28 Mar 2026 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in United Kingdom (PO, Capsule)
- 28 Mar 2026 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in United Kingdom (PO, Capsule)
- 08 Nov 2024 Asceneuron terminates a phase-II trial in Alzheimer's disease (Early-stage disease) in USA (PO) due to strategic decision (NCT06677203)